Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemed Co. stock logo
CHE
Chemed
$561.65
+0.4%
$620.66
$492.84
$654.62
$8.50B0.4683,809 shs70,751 shs
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$67.78
-1.2%
$73.46
$60.01
$82.63
$8.71B0.87886,214 shs1.17 million shs
Qiagen stock logo
QGEN
Qiagen
$42.98
+0.7%
$42.53
$34.74
$47.70
$9.81B0.421.18 million shs1.32 million shs
Repligen Co. stock logo
RGEN
Repligen
$167.05
+0.4%
$180.81
$110.45
$211.13
$9.33B1.03538,521 shs454,984 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemed Co. stock logo
CHE
Chemed
+0.42%+0.24%-11.39%-6.56%+2.05%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
-1.20%-7.32%-7.71%-10.98%-15.29%
Qiagen stock logo
QGEN
Qiagen
+0.68%+3.19%+2.53%-1.22%-7.23%
Repligen Co. stock logo
RGEN
Repligen
+0.44%+0.28%-5.79%-14.84%+2.21%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chemed Co. stock logo
CHE
Chemed
4.828 of 5 stars
2.53.03.34.92.52.52.5
Henry Schein, Inc. stock logo
HSIC
Henry Schein
4.4961 of 5 stars
3.23.00.03.41.92.52.5
Qiagen stock logo
QGEN
Qiagen
4.506 of 5 stars
2.35.00.04.52.41.72.5
Repligen Co. stock logo
RGEN
Repligen
3.901 of 5 stars
2.42.00.04.51.72.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemed Co. stock logo
CHE
Chemed
3.00
Buy$681.0021.25% Upside
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.36
Hold$81.0919.64% Upside
Qiagen stock logo
QGEN
Qiagen
2.56
Moderate Buy$50.9518.53% Upside
Repligen Co. stock logo
RGEN
Repligen
2.89
Moderate Buy$197.7518.38% Upside

Current Analyst Ratings

Latest HSIC, CHE, QGEN, and RGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Repligen Co. stock logo
RGEN
Repligen
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$230.00 ➝ $200.00
5/1/2024
Qiagen stock logo
QGEN
Qiagen
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$55.00 ➝ $45.00
3/6/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$82.00 ➝ $88.00
3/6/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$74.00 ➝ $81.00
3/4/2024
Chemed Co. stock logo
CHE
Chemed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$604.00 ➝ $712.00
2/29/2024
Chemed Co. stock logo
CHE
Chemed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$625.00 ➝ $650.00
2/28/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetIn-Line ➝ In-Line$79.00 ➝ $83.00
2/28/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$82.00 ➝ $90.00
2/26/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$78.00 ➝ $86.00
2/26/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$78.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemed Co. stock logo
CHE
Chemed
$2.26B3.76$24.66 per share22.78$78.17 per share7.18
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.34B0.71$6.60 per share10.27$33.01 per share2.05
Qiagen stock logo
QGEN
Qiagen
$1.94B5.06$3.14 per share13.67$15.77 per share2.73
Repligen Co. stock logo
RGEN
Repligen
$638.76M14.61$3.04 per share54.97$35.27 per share4.74

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemed Co. stock logo
CHE
Chemed
$272.51M$18.5830.2323.422.2912.36%30.52%20.13%7/24/2024 (Estimated)
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$416M$3.1521.5212.171.703.37%14.03%6.22%5/7/2024 (Confirmed)
Qiagen stock logo
QGEN
Qiagen
$341.30M$1.4928.8219.103.6117.38%12.59%7.67%8/13/2024 (Estimated)
Repligen Co. stock logo
RGEN
Repligen
$41.58M$0.25668.2380.315.442.44%3.95%2.90%8/7/2024 (Estimated)

Latest HSIC, CHE, QGEN, and RGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$0.99N/A-$0.99N/AN/AN/A  
5/1/2024Q1 2024
Repligen Co. stock logo
RGEN
Repligen
$0.29$0.28-$0.01$0.52$150.06 million$151.31 million    
4/29/2024Q1 24
Qiagen stock logo
QGEN
Qiagen
$0.44$0.46+$0.02$0.56$453.91 million$459.00 million    
4/24/2024Q1 2024
Chemed Co. stock logo
CHE
Chemed
$5.09$4.68-$0.41$5.12$587.18 million$589.23 million    
2/27/2024Q4 2023
Chemed Co. stock logo
CHE
Chemed
$6.25$6.60+$0.35$7.30$586.64 million$585.90 million    
2/27/202412/31/2023
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$0.70$0.66-$0.04$1.19$3.00 billion$3.02 billion      
2/21/2024Q4 2023
Repligen Co. stock logo
RGEN
Repligen
$0.33$0.33N/A$1.12$155.38 million$155.74 million    
2/6/2024Q4 23
Qiagen stock logo
QGEN
Qiagen
$0.55$0.55N/A$0.68$500.77 million$509.00 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chemed Co. stock logo
CHE
Chemed
$1.600.28%+5.73%8.61%15 Years
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
N/AN/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A

Latest HSIC, CHE, QGEN, and RGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2024
Chemed Co. stock logo
CHE
Chemed
quarterly$0.400.27%2/23/20242/26/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemed Co. stock logo
CHE
Chemed
N/A
1.91
1.88
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.45
1.67
1.00
Qiagen stock logo
QGEN
Qiagen
0.25
1.84
1.62
Repligen Co. stock logo
RGEN
Repligen
0.26
6.35
5.75

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Chemed Co. stock logo
CHE
Chemed
95.85%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Qiagen stock logo
QGEN
Qiagen
70.00%
Repligen Co. stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Chemed Co. stock logo
CHE
Chemed
3.32%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.14%
Qiagen stock logo
QGEN
Qiagen
9.00%
Repligen Co. stock logo
RGEN
Repligen
1.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chemed Co. stock logo
CHE
Chemed
15,08715.14 million14.64 millionOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000128.48 million127.02 millionOptionable
Qiagen stock logo
QGEN
Qiagen
5,967228.20 million207.67 millionOptionable
Repligen Co. stock logo
RGEN
Repligen
1,78355.88 million55.17 millionOptionable

HSIC, CHE, QGEN, and RGEN Headlines

SourceHeadline
Van ECK Associates Corp Has $8.37 Million Stake in Repligen Co. (NASDAQ:RGEN)Van ECK Associates Corp Has $8.37 Million Stake in Repligen Co. (NASDAQ:RGEN)
marketbeat.com - May 4 at 6:36 AM
Q2 2024 EPS Estimates for Repligen Co. Cut by William Blair (NASDAQ:RGEN)Q2 2024 EPS Estimates for Repligen Co. Cut by William Blair (NASDAQ:RGEN)
americanbankingnews.com - May 4 at 1:40 AM
Leerink Partnrs Analysts Increase Earnings Estimates for Repligen Co. (NASDAQ:RGEN)Leerink Partnrs Analysts Increase Earnings Estimates for Repligen Co. (NASDAQ:RGEN)
americanbankingnews.com - May 4 at 1:40 AM
Repligen First Quarter 2024 Earnings: EPS Misses ExpectationsRepligen First Quarter 2024 Earnings: EPS Misses Expectations
finance.yahoo.com - May 3 at 9:05 PM
Repligen Co. Expected to Post Q2 2024 Earnings of $0.33 Per Share (NASDAQ:RGEN)Repligen Co. Expected to Post Q2 2024 Earnings of $0.33 Per Share (NASDAQ:RGEN)
marketbeat.com - May 3 at 7:29 AM
Repligen Corporation (NASDAQ:RGEN) Q1 2024 Earnings Call TranscriptRepligen Corporation (NASDAQ:RGEN) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 2 at 4:08 PM
Repligen (NASDAQ:RGEN) Issues  Earnings ResultsRepligen (NASDAQ:RGEN) Issues Earnings Results
marketbeat.com - May 2 at 2:16 PM
Repligen (NASDAQ:RGEN) Price Target Cut to $200.00 by Analysts at JPMorgan Chase & Co.Repligen (NASDAQ:RGEN) Price Target Cut to $200.00 by Analysts at JPMorgan Chase & Co.
marketbeat.com - May 2 at 1:32 PM
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat EstimatesRepligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
zacks.com - May 2 at 12:26 PM
Repligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...Repligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...
finance.yahoo.com - May 2 at 11:08 AM
Q1 2024 Repligen Corp Earnings Call TranscriptQ1 2024 Repligen Corp Earnings Call Transcript
gurufocus.com - May 2 at 1:01 AM
Repligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst ProjectionsRepligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst Projections
finance.yahoo.com - May 1 at 1:33 PM
RGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024RGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024
investorplace.com - May 1 at 1:02 PM
Repligen (NASDAQ:RGEN) Issues FY 2024 Earnings GuidanceRepligen (NASDAQ:RGEN) Issues FY 2024 Earnings Guidance
marketbeat.com - May 1 at 11:33 AM
Repligen (RGEN) Misses Q1 Earnings EstimatesRepligen (RGEN) Misses Q1 Earnings Estimates
zacks.com - May 1 at 9:51 AM
Repligen: Q1 Earnings SnapshotRepligen: Q1 Earnings Snapshot
wtop.com - May 1 at 8:32 AM
Repligen reports mixed Q1 results; reaffirms FY24 outlookRepligen reports mixed Q1 results; reaffirms FY24 outlook
msn.com - May 1 at 8:32 AM
Repligen Reports First Quarter 2024 Financial ResultsRepligen Reports First Quarter 2024 Financial Results
globenewswire.com - May 1 at 7:30 AM
RGEN Quantitative Stock AnalysisRGEN Quantitative Stock Analysis
nasdaq.com - April 29 at 10:44 AM
Repligen (NASDAQ:RGEN) Shares Gap Up to $157.48Repligen (NASDAQ:RGEN) Shares Gap Up to $157.48
americanbankingnews.com - April 25 at 5:44 AM
Repligen Co. (NASDAQ:RGEN) Stake Cut by New York State Common Retirement FundRepligen Co. (NASDAQ:RGEN) Stake Cut by New York State Common Retirement Fund
marketbeat.com - April 24 at 8:43 AM
Repligen (RGEN) to Release Earnings on WednesdayRepligen (RGEN) to Release Earnings on Wednesday
americanbankingnews.com - April 24 at 5:52 AM
Should be Confident in Repligen Corporation (RGEN)’s Long-Term Growth Potential?Should be Confident in Repligen Corporation (RGEN)’s Long-Term Growth Potential?
finance.yahoo.com - April 23 at 2:54 PM
Positive Report for Repligen (RGEN) from Craig-HallumPositive Report for Repligen (RGEN) from Craig-Hallum
markets.businessinsider.com - April 19 at 3:20 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Chemed logo

Chemed

NYSE:CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Henry Schein logo

Henry Schein

NASDAQ:HSIC
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Qiagen logo

Qiagen

NYSE:QGEN
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Repligen logo

Repligen

NASDAQ:RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.